Why the study?
Do individual oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce medical costs for clinical events compared to warfarin in non-valvular atrial fibrillation patients aged ≥75 and <75 years?
Do individual oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce medical costs for clinical events compared to warfarin in non-valvular atrial fibrillation patients aged ≥75 and <75 years?
Compared to warfarin, apixaban and rivaroxaban are associated with reduced medical costs for clinical events in NVAF patients regardless of age, whereas dabigatran reduces costs only in patients <75 years old.
No takes yet. Share an insight, caveat, or question.
May inform age-specific anticoagulant choice to reduce NVAF event costs; extends observational economic data but leaves open randomized confirmation.
Deitelzweig et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: